Factor IX concentrate

Factor IX concentrate
Names
Trade namesHaemonine, Benefix, others
Other namesFactor IX fraction[1]
Clinical data
Main usesHaemophilia B[2]
Side effectsAnxiety, shortness of breath, allergic reactions, nausea, back pain[1]
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
Routes of
use		Intravenous[2]

Factor IX concentrate, sold under the brand names Haemonine and Benefix among others, is a medication used to treat haemophilia B.[2] Specifically they are used to treat and prevent bleeding.[2] They are given by injection into a vein.[2]

Common side effects include anxiety, shortness of breath, allergic reactions, nausea, and back pain.[1] Other side effects may include angioedema and chest pain.[1] Antibodies that block its ability to work may also develop.[2] It should not be used in disseminated intravascular coagulation.[1] They are manufactured versions of factor IX made from human plasma or by recombinant methods.[2] Risks from versions made from plasma include infection.[2]

Factor IX concentrate became available in the late 1960s, while recombinant versions were approved in 1997.[2][3] It is on the World Health Organization's List of Essential Medicines.[4] In the United Kingdom 1,000 units of the recombinant or plasma derived versions costs the NHS about £600 as of 2023.[5] Longer acting versions are also available.[2]

References

  1. 1 2 3 4 5 "Factor IX fraction, dried [Specialist drug]". BNF. Archived from the original on 16 September 2023. Retrieved 13 September 2023.
  2. 1 2 3 4 5 6 7 8 9 10 Konkle, Barbara A (9 February 2023). Hemophilia B. GeneReviews. Archived from the original on 20 October 2019. Retrieved 13 September 2023.
  3. ↑ "Hemophilia: From Plasma to Recombinant Factors". 2008. Archived from the original on 29 May 2023. Retrieved 13 September 2023.
  4. ↑ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
  5. ↑ "Factor IX fraction, dried [Specialist drug] Medicinal forms". BNF. Archived from the original on 13 September 2023. Retrieved 13 September 2023.
This article is issued from Wmcloud. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.